《半新股》开拓药业-B(09939.HK)由纪录低急弹21%高见17.48元 聘ABI研治新冠肺炎药物
开拓药业-B(09939.HK)扭四连跌,股价由上市低位急弹重越10天及20天线(15.25-15.32元),最高见17.48元,现造17.34元,急弹21%,成交急增至598万股,创逾一个月高,涉资9,736万元。
开拓药业是一间仍未有盈利生物公司。股份於5月22日以每股20.15元上市,首挂日高见22.95元已行人止步,上市翌日收市价开始「潜水」至今。
开拓药业公布,全资子公司苏州开拓药已订立临床试验研协议,聘请美国生物公司Applied Biology Inc.(ABI)进行集团在研药物普克鲁胺(GT0918)治疗新冠肺炎(COVID-19)研究。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.